Showing 1501-1510 of 2839 results for "".
- FDA Clears Caliway’s Phase 3 CBL-514 Trial for Abdominal Fat Reductionhttps://modernaesthetics.com/news/fda-clears-caliways-phase-3-cbl-514-trial-for-abdominal-fat-reduction/2487183/Caliway Biopharmaceuticals announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug application for CBL-0302, also known as SUPREME-02, its second global pivotal phase 3 study of CBL-514 for abdominal subcutaneous fat reduction.1 The IND pass
- SCALE 2026: Practical Strategies for Treating GLP-1 RA–Related Aesthetic Changeshttps://modernaesthetics.com/news/scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487146/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1 receptor agonists (RA)–mediated weight reduction. During a presentation at the 2026 Music City SCALE meeting
- SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lineshttps://modernaesthetics.com/news/scale-2026-ipsen-reports-phase-2-corabotase-data-in-glabellar-lines/2487141/Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee. The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng ac
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://modernaesthetics.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- SCALE 2026: Ipsen to Present Phase II Corabotase Datahttps://modernaesthetics.com/news/scale-2026-ipsen-to-present-phase-ii-corabotase-data/2487087/Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule. Corabotase is described by Ipsen as a custom-designed recombinant neuroi
- Rapalogix Health Launches Re-Q Pro-Longevity Serum with Focus on Cellular Skin Aginghttps://modernaesthetics.com/news/rapalogix-health-launches-re-q-pro-longevity-serum-with-focus-on-cellular-skin-aging/2487003/Rapalogix Health has introduced its new Re-Q Pro-Longevity Face Serum during a virtual launch event on Thursday, May 7, featuring co-Founder and board-certified dermatologist Doris Day, MD, and co-Founder and CEO Rahul Mehta. The webinar focused on the science behind the product and the company’s
- iS Clinical Launches New Eye Gel Highlighting Multimodal Periocular Carehttps://modernaesthetics.com/news/is-clinical-launches-new-eye-gel-highlighting-multimodal-periocular-care/2486957/A new topical formulation targeting the periocular region is entering the aesthetics market, with iS Clinical announcing the launch of GeneXC Firming Eye Gel. The product is designed to address common concerns such as laxity, uneven tone, and dehydration in the delicate eye area. The formu
- Allergan Aesthetics Launches Skin Cancer Awareness Month Initiativehttps://modernaesthetics.com/news/allergan-aesthetics-launches-skin-cancer-awareness-month-initiative/2486944/Allergan Aesthetics, an AbbVie company, launched a charitable initiative for Skin Cancer Awareness Month that will support The Skin Cancer Foundation through its Allē loyalty program. Throughout May, the company will donate $10 to The Skin Cancer Foundation for every new person who joins A
- Aesthetic Record Acquires JOYA Health to Expand Employer-Linked Skin Care Accesshttps://modernaesthetics.com/news/aesthetic-record-acquires-joya-health-to-expand-employer-linked-skin-care-access/2486904/Aesthetic Record, a widely used electronic medical record (EMR) and practice management platform in aesthetics, has announced its acquisition of JOYA Health, a company focused on employer-sponsored skin health benefits. The transaction underscores a broader trend toward specialized, consumer-driv
- Dermalogica Enters Device Market With FDA-Cleared Microneedling Systemhttps://modernaesthetics.com/news/dermalogica-enters-device-market-with-fda-cleared-microneedling-system/2486887/Dermalogica has announced the launch of its PRO Pen Microneedling System following US Food and Drug Administration (FDA) 510(k) clearance, marking the company’s first entry into the medical device category. The device is indicated for the treatment of facial acne scars in adults aged 22 years and